6Yamazaki T,Kume H,Murase S,et al.Epidemiology of visceral mycoses:analysis of data in annual of the pathological autopsy cases in Japan[].Journal of Clinical Microbiology.1999
7Ghannoum MA,and ice LB.Antifungal agents:mode of action,em-chanisms of action,mechanisms of resistance,and correlation of these mechanisms with bacterial resistance[].Clinical Microbiology Reviews.1999
8Meis J,Petrou M,Bille J,et al.Aglobal evaluation of the suscep-tibility of candida species to fluconazole by disk diffusion[].Diagnostic Microbiology and Infectious Disease.2000
9Krcmery V,Barnes AJ.Non-albicans Candida spp causing fungae-mia:pathogenicity and antifungal resistance[].Journal of Hospital Infection.2002
10Martin D,Persat F,Piens MA,et al.Candida species distribution in bloodstream cultures in Lyon,France,1998-2001[].European Journal of Clinical Microbiology and Infectious Diseases.2005
7Morrow J D. Fluconazol: a new triazole antifungal agent[J]. Am J Med Sci, 1991, 302(2): 129-132.
8Robinson P A, Knirsch A K, Joseph J A. Fluconazole for lifethreatening fungal infections in patients who cannot be treated with conventional antifungal agents[J]. Rev Infect Dis, 1990, 12(Suppl 3): s349-363.
9National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard. NCCLS document M27-A2. Wayne. Pennsylvania: NCCLS,2002.1-29
10Godoy P, Tiraboschi IN, Severo LC, et al. Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals. Mem Inst Oswaldo Cruz, 2003,98:401-405.
